Related Experiment Video
Updated: Jun 15, 2026

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
Published on: September 17, 2021
Association of the manganese superoxide dismutase polymorphism with vasospastic angina pectoris
Hajime Fujimoto1, Hisae Kobayashi, Ken Ogasawara
1Department of Cardiovascular Medicine, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo, Japan. hafujimoto-circ@umin.ac.jp
Background:
Vasospastic angina (VSA) is closely related to endothelial dysfunction caused by oxidative damage. Manganese superoxide dismutase (MnSOD) is an antioxidant enzyme that functions in mitochondria. There are two genetic variants of MnSOD arising from a substitution of an alanine for a valine in the signal peptide. We previously reported that the valine allele of MnSOD decreases the mitochondrial MnSOD (mtMnSOD) activity. Here, we investigated the association of the MnSOD polymorphism (Ala16Val) with VSA.
Methods And Results:
Blood samples were collected from 618 healthy subjects who did not have any symptoms or other evidence suggesting angina pectoris, and 228 patients who underwent coronary angiography on suspicion of angina, and were diagnosed to have VSA by acetylcholine test. MnSOD genotype of each subject was determined by real-time polymerase chain reaction. The valine allele frequency was higher in the VSA patients (0.890) than in the healthy subjects (0.839) [odds ratio (OR)=1.55, p=0.0085]. In healthy subjects the MnSOD genotype distribution was as follows: alanine/alanine 1.9%, alanine/valine 28.3%, and valine/valine 69.8%, and in VSA patients the prevalence was: alanine/alanine 1.3%, alanine/valine 19.3%, and valine/valine 79.4%. Thus, the valine allele was closely associated with VSA (p=0.019). Multivariate logistic regression analysis showed valine/valine homozygosity to be an independent risk factor for VSA (OR=2.02, 95% CI 1.43, 2.85; p=0.0012).
Conclusion:
The valine variant of MnSOD signal peptide increases the risk of VSA.
Related Concept Videos
Mitral Stenosis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Angina III: Clinical Manifestations and Assessment
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
